ReviewMolecular immunology2009
Complement Receptor 1: disease associations and therapeutic implications.
Review in Molecular immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Analysis of human neutrophil phenotypes as biomarker to monitor exercise-induced immune changes.Journal of leukocyte biology · 2021Trial
- Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.Haematologica · 2014Trial
- Genetics of intracerebral hemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
- Multi-omics analysis identifies macrophage immunometabolic signatures in ulcerative colitis.Frontiers in cellular and infection microbiology · 2026Article
- Proteomics identifies complement protein signatures in patients with primary biliary cholangitis.European journal of medical research · 2025Article
- The grand escape - how pathogens outsmart the human complement system.Immunobiology · 2025Review
- Complement Receptor 1 Is a Potential Extracerebral Factor Promoting α-Synuclein Pathology.Molecular neurobiology · 2025Article
- Identification and Validation of Potential Biomarkers and Therapeutic Targets of COVID-19-related Depression.Combinatorial chemistry & high throughput screening · 2025Article
- Multi-omics analysis reveals neutrophil heterogeneity and key molecular drivers in sepsis-associated acute kidney injury.Frontiers in immunology · 2025Article
- The Dual Role of Amyloid Beta-Peptide in Oxidative Stress and Inflammation: Unveiling Their Connections in Alzheimer's Disease Etiopathology.Antioxidants (Basel, Switzerland) · 2024Review
- Molecular Responses of the Eukaryotic Cell Line INT407 on the InternalizedPathogens (Basel, Switzerland) · 2024Article
- Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease.Clinical and experimental immunology · 2024Article
- Knobs, Adhesion, and Severe Falciparum Malaria.Tropical medicine and infectious disease · 2023Review
- Association between Rhesus Blood Groups and Malaria Infection: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2023Review
- The Complement System in Kidney Transplantation.Cells · 2023Review
- Molecular Simulation Study on the Interaction between Porcine CR1-like and C3b.Molecules (Basel, Switzerland) · 2023Article
- Structural biology of complement receptors.Frontiers in immunology · 2023Review
- Complement C4-deficient mice have a high mortality rate during PTZ-induced epileptic seizures, which correlates with cognitive problems and the deficiency in the expression of Egr1 and other immediate early genes.Frontiers in cellular neuroscience · 2023Article
- The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease.Antioxidants & redox signaling · 2022Review
- Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE).Lupus science & medicine · 2022Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exaggerated complement activation is a key event in the pathogenesis of a range of autoimmune and inflammatory diseases. Complement Receptor 1 (CR1) has emerged as a molecule of immense interest in gaining insight to the susceptibility, pathophysiology, diagnosis, prognosis and therapy of such diseases. This review brings forth a composite view of the current understanding on the structure, functions, genetics, disease associations and therapeutic implications of CR1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.